In a research by Li et al. [474], combining anti‐HER2 and anti‐CD47 therapy in both in vivo and in vitro models of ovarian cancer (SKOV3) and breast cancer (BT474) enhanced antitumor activity, reduced the toxicity, and extended survival. Here, ERBB2 is linked to ovarian carcinoma.